News

NX Prenatal Inc., focused on development of proprietary blood-based, early warning molecular diagnostic tests for adverse pregnancy outcomes, announced today the publication of a peer-reviewed study, "Circulating Microparticle Proteins Obtained in the Late First Trimester Predict Spontaneous Preterm Birth at Less than 35 Weeks Gestation: A Panel Validation with Specific Characterization by Parity" in the American Journal of Obstetrics & Gynecology. The publication is available online: https://doi.org/10.1016/j.ajog.2019.01.220. ​

NX Prenatal Inc., a privately held women’s healthcare molecular diagnostic company, announced today that it has entered into a strategic collaboration with Milu Labs, whose mission is to become the leading diagnostics company in Asia with a focus on maternal fetal medicine and women’s health.

NX Prenatal Inc., a privately held women’s healthcare molecular diagnostic company, announced today that expanding applications of its proprietary NeXosome® liquid biopsy platform were presented at recent scientific conferences.

NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that it has entered into a collaboration with Indiana University School of Medicine to further validate its early pregnancy biomarker panels that predict Spontaneous Preterm Birth (SPTB) and to further develop its biomarker panels for Preeclampsia (PE).

NX Prenatal today announced that senior management will participate in the Solebury Trout 4th Annual Private Company Showcase in New York City. The event is attended by investors focused on private, emerging stage biotech companies and co-hosted by Davis Polk, BMO, RR Donnelley and CFGI.

NX Prenatal Inc., a privately held women’s healthcare molecular diagnostic company, announced today that new clinical study data will be presented at the Society of Reproductive Investigation’s (SRI) 65th Annual Scientific Meeting in San Diego, California, on March 9th, 2018.